AstraZeneca PLC Files 6-K Shareholding Report
Ticker: AZN · Form: 6-K · Filed: Sep 25, 2025 · CIK: 901832
| Field | Detail |
|---|---|
| Company | Astrazeneca PLC (AZN) |
| Form Type | 6-K |
| Filed Date | Sep 25, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.25, $81.0499 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-issuer, shareholding
Related Tickers: AZN
TL;DR
AZN filed a routine 6-K for shareholding info, nothing major to see here.
AI Summary
AstraZeneca PLC filed a Form 6-K on September 25, 2025, reporting its shareholding information as required for foreign issuers. The filing indicates the company is submitting its annual reports under Form 20-F. No specific financial transactions or new developments were detailed in this particular filing.
Why It Matters
This filing is a routine disclosure for foreign issuers like AstraZeneca, providing transparency on shareholding structures and regulatory compliance with the SEC.
Risk Assessment
Risk Level: low — This is a standard, routine filing for a foreign issuer and does not contain new material information that would typically impact risk.
Key Players & Entities
- AstraZeneca PLC (company) — Registrant
- 001-11960 (company) — SEC File Number
- 20250925 (date) — Filing Date
- Form 6-K (document) — Filing Type
- Form 20-F (document) — Annual Report Form
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to keep information current, typically including information made or is about to be made public in their home country.
What is the filing date of this specific Form 6-K?
The filing date of this Form 6-K is September 25, 2025.
Which annual report form does AstraZeneca PLC indicate it files?
AstraZeneca PLC indicates it files its annual reports under cover of Form 20-F.
What is the SEC file number for AstraZeneca PLC?
The SEC file number for AstraZeneca PLC is 001-11960.
Does this filing indicate any new financial results or material events?
No, this filing is a routine report of foreign issuer shareholding information and does not detail new financial results or material events.
Filing Stats: 702 words · 3 min read · ~2 pages · Grade level 19.7 · Accepted 2025-09-25 13:27:10
Key Financial Figures
- $0.25 — f the Company's ordinary shares of $0.25 each.   Further details are se
- $81.0499 — #xA0; Price(s)   Volume(s) $81.0499   9.0737 d)   Aggre
Filing Documents
- a8844a.htm (6-K) — 39KB
- 0001654954-25-011107.txt ( ) — 40KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.     AstraZeneca PLC     Date: 25 September 2025     By: /s/ Matthew Bowden   Name: Matthew Bowden   Title: Company Secretary